Abstract. In 20 patients with duodenal ulcer we measured serum prolactin levels following acute and long-term cimetidine administration. In addition, in 20 healthy volunteers we studied the effect of pre-treatment with bromocriptine, metergoline, nomifensine and cyproheptadine on cimetidine-induced prolactin release. Intravenous cimetidine stimulated prolactin secretion in patients and in normal subjects. In the latter, bromocriptine and metergoline pre-administration blunted the release of prolactin in response to iv cimetidine whereas nomifensine and cyproheptadine were ineffective. Long-term treatment with cimetidine (1.2 g daily for 3 months) had no effect on prolactin secretion in the 20 patients studied. No 
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It has been shown that cimetidine, an H2 receptor blocking agent, releases prolactin in man (Carlson & Ippoliti 1977; Bohnet et al. 1978) . Moreover, side effects such as gynaecomastia and galactorrhoea have been reported in patients treated with the drug (Hall 1976; Delle Faveetal. 1977; Bateson etal. 1977 ).
We studied the effects of both acute and chronic cimetidine treatment on serum prolactin levels in 20 patients with duodenal ulcers. Additional stu¬ dies were carried out on 20 normal subjects in order to elucidate the mechanism(s) responsible for cimetidine-induced prolactin secretion. Blood samples for hormone assay were centrifuged and serum specimens stored at -20°C until assayed. All samples from each subject were processed in duplicate in the same assay. Serum prolactin was measured by a specific double-antibody radioimmunoassay (McNeilly assay variations were 3% and 7%, respectively. The results are reported in ng/ml. In our laboratory fasting prolactin levels in normal male and female subjects were found to be less than 10 ng/ml and 22 ng/ml, respective¬ ly. All the results are reported as means ± sf.m. The two-tailed, paired and unpaired Student's ¿-tests were used for a statistical analvsis of the data.
Materials and Methods

Results
The results are reported in Fig. 1 (Bohnet et al. 1978) . There¬ fore, the failure of chronic oral cimetidine to stimulate prolactin secretion is presumably not due to an organismic adaptation to the agent. This confirms the hypothesis that cimetidine-induced prolactin release is dose-related. When given oral¬ ly, the drug cannot reach blood levels sufficient to trigger prolactin secretion (Burland et al. 1979 ).
As for the mechanism of cimetidine-induced prolactin secretion, previous reports have sug¬ gested that this may be due to an effect on H2 central receptors (Carlson & Ippoliti 1977 (Müller et al. 1978; Másala et al., in press). However, it may be that bromocriptine and metergoline inhibit the prolactin-releasing action of cimetidine by acting directly at the pituitary level, a site of action that is not shared by nomifen¬ sine (Schacht et al. 1977 ). This explanation is consistent with reports demonstrating that nomi¬ fensine does not blunt the prolactin release in response to synthetic TRH which acts directly on pituitary lactotropes (Scanlon et al. 1977) . The failure of cyproheptadine to interfere with prolac¬ tin secretion confirms previous data (Delitala et al. chanism responsible for the onset of gynaecomastia and galactorrhoea. As a possibility, it should be mentioned that recent reports attribute an antiandrogenic effect to cimetidine in rats that could be responsible for the side effects in question (Winters et al. 1979 ). The safety of long-term treatment with cimetidine in humans needs further investigation.
